Home/Pipeline/Bispecifics

Bispecifics

Autoimmune Diseases

IND-EnablingPreclinical

Key Facts

Indication

Autoimmune Diseases

Phase

IND-Enabling

Status

Preclinical

Company

Shattuck Labs

About Shattuck Labs

Shattuck Labs is a clinical-stage biotech with a mission to establish DR3 blockade as a new standard of care in inflammatory and immune-mediated diseases. The company has rapidly advanced its lead asset, SL-325, into Phase 2 development for IBD, leveraging a differentiated receptor-blocking strategy to potentially overcome limitations of existing TL1A-targeting therapies. Its strategy hinges on demonstrating best-in-class remission rates and a favorable immunogenicity profile to capture significant market share in the competitive IBD landscape.

View full company profile

Therapeutic Areas

Inflammatory Bowel Disease Autoimmune Diseases

Other Autoimmune Diseases Drugs

Drug	Company	Phase	Status
Humira (Adalimumab) Biosimilar	NeuClone	Early Preclinical	Active
HBM7020	Harbour BioMed	Discovery	Out-Licensed
R2006	Harbour BioMed	Discovery	Active (Global)
R7027	Harbour BioMed	Discovery	Active (Global)
ImmCelz™ Platform	Creative Medical Technology Holdings	Preclinical	Research
Not specified in provided content	3Sbio	Various	Active
Gavocabtagene autoleucel	astellas	Phase 1/2	Active
TYK-101	TYK Medicines	Phase 1	Active
HCB206	HanchorBio	Preclinical	Active
miR-124 Activator	Formation Bio	Phase 2	Active
Autologous Cell Therapy Collaboration	Lupagen	Preclinical	Active
Autoimmune Diagnostics Leadership Initiative	Vibrant America Clinical Laboratory	Commercial	Active